Analysis and Commentary STEVEN GROSSMAN 10/9/20 Analysis and Commentary STEVEN GROSSMAN 10/9/20 Webinar on Budget, Workload, and Other Priorities for CDER Read More Analysis and Commentary STEVEN GROSSMAN 10/1/20 Analysis and Commentary STEVEN GROSSMAN 10/1/20 Understanding the Short-Term CR Read More Advocacy at a Glance STEVEN GROSSMAN 10/2/20 Advocacy at a Glance STEVEN GROSSMAN 10/2/20 FDA to Be Funded under Short-Term Continuing Resolution through December 11 Read More Analysis and Commentary STEVEN GROSSMAN 9/25/20 Analysis and Commentary STEVEN GROSSMAN 9/25/20 How FDA is Funded, ... and Why Read More Advocacy at a Glance STEVEN GROSSMAN 9/25/20 Advocacy at a Glance STEVEN GROSSMAN 9/25/20 FDA Will Begin Fiscal Year 2021 With CR Funding Read More Analysis and Commentary STEVEN GROSSMAN 9/18/20 Analysis and Commentary STEVEN GROSSMAN 9/18/20 Public Trust in the US FDA Read More Advocacy at a Glance STEVEN GROSSMAN 9/18/20 Advocacy at a Glance STEVEN GROSSMAN 9/18/20 Dr. Cavazzoni and Dr. Stein to Address FDA Members and Media on October 16 Read More Advocacy at a Glance STEVEN GROSSMAN 9/11/20 Advocacy at a Glance STEVEN GROSSMAN 9/11/20 Following the Science to Protect Public Health Read More Advocacy at a Glance STEVEN GROSSMAN 9/11/20 Advocacy at a Glance STEVEN GROSSMAN 9/11/20 Alliance Webinar with CDER Postponed, Will Be Rescheduled Shortly Read More Analysis and Commentary STEVEN GROSSMAN 9/3/20 Analysis and Commentary STEVEN GROSSMAN 9/3/20 Understanding Tom Frieden's Proposed HDO Read More Advocacy at a Glance STEVEN GROSSMAN 9/4/20 Advocacy at a Glance STEVEN GROSSMAN 9/4/20 Congress Expected to Pass a Continuing Resolution in September, but Key Details Remain to be Resolved Read More Analysis and Commentary STEVEN GROSSMAN 8/14/20 Analysis and Commentary STEVEN GROSSMAN 8/14/20 "Somehow the CR Will Pass", But When? Read More Advocacy at a Glance STEVEN GROSSMAN 8/14/20 Advocacy at a Glance STEVEN GROSSMAN 8/14/20 Party Platforms Don’t Matter, Probably Read More Analysis and Commentary STEVEN GROSSMAN 8/7/20 Analysis and Commentary STEVEN GROSSMAN 8/7/20 CDER Priorities: During the Pandemic and for 2021 Read More Advocacy at a Glance STEVEN GROSSMAN 8/7/20 Advocacy at a Glance STEVEN GROSSMAN 8/7/20 What We Learned: A Meeting with CDER Deputy Center Director for Operations Dr. Patrizia Cavazzoni Read More Analysis and Commentary STEVEN GROSSMAN 8/1/20 Analysis and Commentary STEVEN GROSSMAN 8/1/20 About the Alliance for a Stronger FDA Read More Advocacy at a Glance STEVEN GROSSMAN 8/1/20 Advocacy at a Glance STEVEN GROSSMAN 8/1/20 House Will Pause Once It Has Completed 10 of 12 Appropriations Bills Read More Advocacy at a Glance STEVEN GROSSMAN 7/26/20 Advocacy at a Glance STEVEN GROSSMAN 7/26/20 FY 21 Appropriation: Qs&As Read More Advocacy at a Glance STEVEN GROSSMAN 7/26/20 Advocacy at a Glance STEVEN GROSSMAN 7/26/20 House Appropriations Minibus Containing FY 21 Ag/FDA Funding Advances Read More Analysis and Commentary STEVEN GROSSMAN 7/18/20 Analysis and Commentary STEVEN GROSSMAN 7/18/20 Why No Movement in the Senate? Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 10/9/20 Analysis and Commentary STEVEN GROSSMAN 10/9/20 Webinar on Budget, Workload, and Other Priorities for CDER Read More
Analysis and Commentary STEVEN GROSSMAN 10/1/20 Analysis and Commentary STEVEN GROSSMAN 10/1/20 Understanding the Short-Term CR Read More
Advocacy at a Glance STEVEN GROSSMAN 10/2/20 Advocacy at a Glance STEVEN GROSSMAN 10/2/20 FDA to Be Funded under Short-Term Continuing Resolution through December 11 Read More
Analysis and Commentary STEVEN GROSSMAN 9/25/20 Analysis and Commentary STEVEN GROSSMAN 9/25/20 How FDA is Funded, ... and Why Read More
Advocacy at a Glance STEVEN GROSSMAN 9/25/20 Advocacy at a Glance STEVEN GROSSMAN 9/25/20 FDA Will Begin Fiscal Year 2021 With CR Funding Read More
Analysis and Commentary STEVEN GROSSMAN 9/18/20 Analysis and Commentary STEVEN GROSSMAN 9/18/20 Public Trust in the US FDA Read More
Advocacy at a Glance STEVEN GROSSMAN 9/18/20 Advocacy at a Glance STEVEN GROSSMAN 9/18/20 Dr. Cavazzoni and Dr. Stein to Address FDA Members and Media on October 16 Read More
Advocacy at a Glance STEVEN GROSSMAN 9/11/20 Advocacy at a Glance STEVEN GROSSMAN 9/11/20 Following the Science to Protect Public Health Read More
Advocacy at a Glance STEVEN GROSSMAN 9/11/20 Advocacy at a Glance STEVEN GROSSMAN 9/11/20 Alliance Webinar with CDER Postponed, Will Be Rescheduled Shortly Read More
Analysis and Commentary STEVEN GROSSMAN 9/3/20 Analysis and Commentary STEVEN GROSSMAN 9/3/20 Understanding Tom Frieden's Proposed HDO Read More
Advocacy at a Glance STEVEN GROSSMAN 9/4/20 Advocacy at a Glance STEVEN GROSSMAN 9/4/20 Congress Expected to Pass a Continuing Resolution in September, but Key Details Remain to be Resolved Read More
Analysis and Commentary STEVEN GROSSMAN 8/14/20 Analysis and Commentary STEVEN GROSSMAN 8/14/20 "Somehow the CR Will Pass", But When? Read More
Advocacy at a Glance STEVEN GROSSMAN 8/14/20 Advocacy at a Glance STEVEN GROSSMAN 8/14/20 Party Platforms Don’t Matter, Probably Read More
Analysis and Commentary STEVEN GROSSMAN 8/7/20 Analysis and Commentary STEVEN GROSSMAN 8/7/20 CDER Priorities: During the Pandemic and for 2021 Read More
Advocacy at a Glance STEVEN GROSSMAN 8/7/20 Advocacy at a Glance STEVEN GROSSMAN 8/7/20 What We Learned: A Meeting with CDER Deputy Center Director for Operations Dr. Patrizia Cavazzoni Read More
Analysis and Commentary STEVEN GROSSMAN 8/1/20 Analysis and Commentary STEVEN GROSSMAN 8/1/20 About the Alliance for a Stronger FDA Read More
Advocacy at a Glance STEVEN GROSSMAN 8/1/20 Advocacy at a Glance STEVEN GROSSMAN 8/1/20 House Will Pause Once It Has Completed 10 of 12 Appropriations Bills Read More
Advocacy at a Glance STEVEN GROSSMAN 7/26/20 Advocacy at a Glance STEVEN GROSSMAN 7/26/20 FY 21 Appropriation: Qs&As Read More
Advocacy at a Glance STEVEN GROSSMAN 7/26/20 Advocacy at a Glance STEVEN GROSSMAN 7/26/20 House Appropriations Minibus Containing FY 21 Ag/FDA Funding Advances Read More
Analysis and Commentary STEVEN GROSSMAN 7/18/20 Analysis and Commentary STEVEN GROSSMAN 7/18/20 Why No Movement in the Senate? Read More
